This phase III trial is trying to determine whether adding a targeted cancer drug to hormone treatment in patients with castrate sensitive prostate cancer will result in improved survival outcomes.
This trial is treating patients with castrate sensitive prostate cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are currently receiving treatment for your cancer.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Janssen-Cilag Pty Ltd
Eligible patients will be randomised to receive 200mg or niraparib or a niraparib-placebo, in addition to 1000mg of abiraterone acetate and 5mg of prednisone once daily.
Recruiting Hospitals Read More